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Background: Comparative studies of patients in different sociogeographic/ecological zones may unravel
potential environmental and nutritional factors influencing disease phenotype. In sickle cell disease (SCD), dif-
ferential access to comprehensive care may influence their growth and nutritional status.
Methods: From June 2015 to February 2016, steady-state nutritional parameters of 109 Brazilian and 95
Nigerian children with SCD attending routine clinic visits at Universidade Federal de São Paulo, Brazil and
Obafemi Awolowo University Teaching Hospital, Ile-Ife (Ilesa unit), respectively, were compared.
Results: A relatively high proportion of the children in both centres (23.5%) were wasted [body-mass index
(BMI)-for-age z-score<−2). BMI-for-age z-score, height-for-age z-score, upper arm fat area and fat percentage
were lower in the Nigerian cohorts. More Nigerians, 29.5% (28/95) against 18.3% (20/109) were wasted, and
had short stature, [12.6% (12/95) vs. 3.7% (4/109)] than Brazilians. A higher proportion of Brazilian patients
were overweight or obese (9.2 vs. 4.3%), and taller for age (15.6 vs. 8.4%). None of the Nigerian patients had
severe vitamin D deficiency, only 12.6% (12/95) had suboptimal vitamin D and 1.1% (1/95) had low serum
zinc levels, unlike 79.8% (87/109) of the Brazilian patients with suboptimal vitamin D and 10.1% (11/109)
with low zinc.
Conclusion: Undernutrition is still prevalent among the two cohorts. Nigerian patients were thinner and had
reduced linear growth for age. This observation justifies the continued need for specialized nutritional care for
children with SCD. In addition to hydroxyurea therapy, research is needed to determine appropriate nutritional
intervention and exercise regimens for these children.
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Introduction
SCD is the most common haematological hereditary disease in
Brazil and Nigeria.1,2 It is estimated that about 4% (2–8%) of
the world population carry an abnormal haemoglobin gene,
with sickle cell anaemia (SCA) being the most common form of
haemoglobinopathy.3 Approximately 20–25 million people live
with SCA worldwide, out of which about 12–15 million reside in
sub-Saharan Africa, and annually about 300 000 children with
the gene are born globally.4 The disease affects people across the
globe particularly sub-Saharan Africa, India, Mediterranean and
Southern European countries.5 Ancient and recent population
migrations have also carried the disease to the Caribbean, South
and North America, and Northern Europe.5
Reduced growth and delayed development are common in
children with SCD to the extent that some researchers are advo-
cating the use of modified growth charts when monitoring their
nutritional state.6 Usually, these patients experience a progres-
sive decrease in growth velocity up to adolescence. In addition,
they have a delay in bone maturation, epiphysis fusion during
puberty and sexual development.5 Micronutrients, such as ser-
um zinc, 25-hydroxyvitamin D (25-OHD), selenium and retinol,
are suboptimal in SCD due to reduced appetite and poor dietary
intake, increased energy and metabolic requirements, and
reduced physical activity.7,8 SCD-directed therapies, such as
hydroxyurea (HU) and chronic blood transfusion have been
O
R
IG
IN
A
L
A
R
TI
CL
E
© The Author(s) 2017. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
327
D
ow
nloaded from
 https://academ
ic.oup.com
/inthealth/article/9/6/327/4259766 by U
niversidade Federal de Sï¿½
o Paulo user on 24 August 2020
associated with significant reduction in the overall morbidity
and mortality.9,10 These therapies could possibly improve
growth and nutritional status of children with SCD. While many
Brazilian children with SCD are being treated with hydroxyurea,
the majority of Nigerian children with the disease do not have
access to this drug. Apart from differences in the haplotypes of
SCD between Brazilian and Nigerian patients, important modifi-
able factors such as nutritional status of patients may influence
SCD severity and, hence, its associated morbidity and mortal-
ity.11,12 The predominant SCD haplotype among Brazilian
patients is the Central African Republic, CAR (Bantu) haplotype,
while Benin (BEN) haplotype is the leading haplotype among
Nigerian patients.11,12 The CAR haplotype is usually associated
with a lower level of foetal haemoglobin and, subsequently,
more severe phenotype compared with the BEN haplotype.
Although, in low income countries, children with SCD fre-
quently experience poor growth and impaired nutritional state,
few reports from some high income nations show that these
children are now becoming overweight and obese.6,13 Recent
studies have also shown that obesity-related complications,
such as systemic hypertension, obstructive sleep apnoea, avas-
cular osteonecrosis and asthma, are on the increase in children
and adolescents with SCD.6,13 These comorbidities are asso-
ciated with increased SCD-related mortality.
The SCD phenotype is very variable, and many genetic and envir-
onmental modulating factors have been identified. Comparative
studies of patients in different sociogeographic and ecological zones
afford an opportunity to investigate potential environmental and
other factors that influence the phenotype. This study aimed at
comparing differences in nutritional status as measured by
anthropometric and biochemical variables (serum zinc and 25-
OHD) between two cohorts of children with SCD followed in Ilesa,
Southwest, Nigeria, and São Paulo, Brazil.
Methods
This is a descriptive cross-sectional study in which demographic,
clinical, nutritional and laboratory data of paediatric patients
with SCD in steady state were collected.
Study location
The study was carried out at the paediatric haematology clinics
of the Escola Paulista de Medicina, Universidade Federal de São
Paulo (UNIFESP), Brazil and Obafemi Awolowo University
Teaching Hospital (OAUTH), Ilesa Unit, Nigeria. Nigeria, the lar-
gest country in West Africa with an estimated population of
about 170 million people, is located on latitude 10°N of equator
and longitude 8°E of Greenwich Meridian. It has an abundance
sunlight throughout the year. The Nigerian study participants
are predominantly Yoruba, of Ife-Ijesa extraction, in the south-
western part of the country. Ilesa, the study centre is an urban
city and is located about 250 km north-east of Lagos, the former
Nigerian capital. A typical Yoruba diet is high in carbohydrate.
The paediatric haematology clinic of OAUTH runs weekly and sees
an average of 25 patients/week. A total of about 400 children
with SCD are registered in the clinic. The clinic offers daily
chemoprophylaxis, such as folate and preventive antimalaria
treatment (proguanil). Hydroxyurea is prescribed only when indi-
cated and the patient’s family can afford the cost. Although
oral penicillin prophylaxis is not currently routinely prescribed, all
children are offered Pneumococcal and Haemophilus influenza
type B vaccination.
Brazil, the largest country in South America is located on lati-
tude 10°S and longitude 55°W of Equator. São Paulo city, like
other cities in south-east Brazil, experiences a prolonged annual
period of cold weather and reduced exposure to sunlight. The
population is heterogenous comprising diverse ethnic groups,
including native Latin Americans, African, Asian, Arabs, Jewish,
North American and Europeans, particularly Italians. The paedi-
atric haematology clinic of UNIFESP also runs every week. The
clinic offers comprehensive SCD care, including hydroxyurea and
chronic blood transfusion therapy, transcranial Doppler ultrason-
ography for stroke prevention, and daily folate chemoprophy-
laxis, oral penicillin, Pneumococcal and Haemophilus influenza
type B vaccination are also routinely given.
Patients
The study included 109 Brazilian and 95 Nigerian children aged
4–11 years who had been diagnosed with SCA. They routinely
attend the paediatric haematology clinics of the respective hos-
pitals. All the study participants were in steady state at the time
of recruitment, i.e. they had been free of crisis (painful or
anaemic), infections or any other acute illness for at least four
consecutive weeks, and had not been transfused 3 months prior
to the study.14 All the eligible children that attended the clinics
during the study period (June 2015 to February 2016) were
recruited consecutively. The age limits were set at 11 and 4 years
as only few children among those younger than 4 years are
managed with hydroxyurea and only very few among those old-
er than 11 years are managed without hydroxyurea in Brazil.
Children on a chronic blood transfusion programme, and those
taking medications known to affect growth or nutritional status
(e.g. growth hormone, glucocorticoid therapy) were not included
in the study. Institutional approval was obtained from the Ethics
and Research Committees of the hospitals independently before
commencement of the study. Also, written informed consent
was obtained from each study participant.
Data on the sociodemographics (age, sex and socioeconomic
status) were obtained from each patient through a pretested
questionnaire. Socioeconomic status of the parents was deter-
mined using the occupation of the father and the highest aca-
demic qualification of the mother.15,16 Clinical history and
physical findings, including splenic and liver enlargement were
obtained through a pretested questionnaire and by review of
relevant medical charts. Lifetime SCD complications were as
defined by Ballas et al.14 In addition, the frequencies of vaso-
occlusive episodes, hospitalization and transfusion that occurred
in the previous 12 months were recorded. Acute significant pain-
ful episode was defined as a painful event requiring a hospital
visit, and the use of oral and/or parenteral analgesics.
Growth status
Weight was measured to the nearest 0.1 kg on a scaletronix
digital electronic scale (Scaletronix, White Plains, NY) and height
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to the nearest 0.1 cm with a stadiometer (Holtain, Crymych,
UK). From the weight and height, BMI was calculated as weight
(kg)/height2 (m2). Weight and height were transformed into
z-scores for height/age, weight/age and weight/height, and BMI
for age and sex, and then compared with the reference values
using WHO/National Center for Health Statistics (NCHS) refer-
ence standards.17 Height-for-age z-score<−2 was defined as
stunting, BMI-for-age z-score <−2 (BMI-Z<−2) from the mean
as wasting. Those with BMI-for-age z-score <−2, but >−3 were
moderately wasted, and those with BMI-for-age z-score<−3 as
severely wasted. Overweight was defined as BMI-for-age z score
>2, but ≤+3 from the mean; and obese if BMI-for-age z-score was
>3 from the mean. Normal weight was BMI-for-age z-score within
the mean ±2
Nutritional assessment
The assessment of nutritional status was based on triceps skin-
fold (TSF) thickness, mid-upper arm circumference (MUAC),
upper arm area (UAA), upper arm fat area (UAFA) and upper
arm muscle area (UAMA). Measures of MUAC were combined
with the TSF thickness to calculate UAA, UAFA and UAMA as
shown in the following equations:
( )=( −π ) π
( )=π ( π)
( )= — = ×
UAMA cm MUAC TSF /4
UAA cm /4 MUAC/
UAFA cm UAA UAMA and Fat% UAFA 100/UAA,
2 2
2 2
2
where π is 3.1416.18
MUAC was measured on a freely-hanging left upper arm mid-
way between the acromion and the olecranon process using a
flexible, but non-stretchable tape to the nearest 0.1 cm in all
the subjects. TSF was measured using the Harpenden skinfold
callipers. The skin was pinched between index finger and the
thumb half-way down the back of the arm. This was then gently
gripped by the callipers to measure the skin fold thickness in
millimetres. The mean of two measurements was recorded.
Haematological parameters
Laboratory data such as haematocrit, white blood cell count
and differential, mean corpuscular volume (MCV), mean corpus-
cular haemoglobin (MCH), mean corpuscular haemoglobin con-
centration (MCHC), platelet count and HbF% were obtained.
Complete blood counts and white blood cell count differentials
were performed using auto-haemoanalyser Pentra 60, Horiba®
(HORIBA ABX SAS, Belgium) machine in the Ile-Ife cohort and the
Siemens ADVIA 2120 (Siemens AG, Erlangen, Germany) machine
in the São Paulo cohort. The HbF% was measured using BIO-RAD®
D10 (Bio-Rad Laboratories, Inc., Hercules, CA) high performance
liquid chromatography (HPLC) in both centres.
Serum 25-hydroxyvitamin D and zinc level
Blood samples for serum 25-OHD and zinc were drawn between
8 a.m. and 11 a.m., and centrifuged within 1 hour of collection
at 3000 rev/min for 15 minutes at room temperature to extract
the plasma. The plasma was then divided into aliquots in plain
screw cap specimen bottles and stored frozen at −20°C until ana-
lysed. Analysis of serum 25-OHD levels was done with HPLC in
both centres using a standard protocol. Serum levels ≥30 ng/mL
were considered sufficient, 20–29.9 ng/mL as insufficient, values
<20ng/mL as vitamin D deficiency and values <10ng/mL as
severe deficiency.19 Analysis of serum zinc levels was done using
atomic absorption spectrophotometry in both centres using a
standard protocol. Zinc deficiency was defined as serum zinc
<70ng/ml, normal zinc level as 70–120 ng/ml and high zinc level
as values >120ng/ml.
Statistical analysis
Statistical tests were performed using SPSS version 17.0. Both
parametric and non-parametric tests were used as appropriate,
taking into account the variability and the nature of the distribu-
tions of the variables studied. Kolmogorov–Smirnov statistics was
used to test the normality of the distribution. Continuous variables
were compared according to site with independent sample t-test,
Mann–Whitney test, analysis of variance or Kruskall–Wallis tests,
and categorical variables with Pearson’s χ2 test or Fisher’s exact
test. The statistical significance level for the alpha error was
p≤0.05 and 95% confidence interval exclusion of unity.
Results
Patient characteristics
A total of 204 children, comprising 109 Brazilian children and 95
Nigerian children with SCA were studied. Age and gender distribu-
tion were similar between the two cohorts (Table 1). None of the
Nigerian patients was on hydroxyurea therapy compared with
67.0% (73/109) of the Brazilian patients. 33.0% (36/109) of
Brazilian patients were not on hydroxyurea therapy. More of the
Nigerian children experienced ≥3 significant pain episodes in the
12 months preceding the study than the Brazilian children, 31.6%
(30/95) vs. 15.6% (17/109), p=0.007, 95% CI = 0.2–0.8. However,
the rates of SCD-related admission and transfusion were signifi-
cantly higher among Brazilian than Nigerian patients, 49.5% (54/
109) vs. 31.6% (30/95), p=0.009, 95% CI = 1.2–3.8 and 35
(32.1%) vs. 14 (14.8%), p=0.004, 95% CI = 1.4–5.5, respectively.
Clinical complications
Higher proportions of patients from São Paulo compared with
the Nigerian cohort had histories of ACS, 60.6% (66/109) vs.
29.5% (28/95), p<0.001; splenic sequestration 52.3% (57/109)
vs. 3.2% (3/95), p<0.001 and cholelithiasis 31.2% (34/109) vs.
0% (0/95), p<0.001. Osteomyelitis was, however, more com-
monly diagnosed among Nigerian children with SCD, 16.8%
(16/95) than the Brazilian children, 3.7% (4/109), p=0.023.
Nutritional status
BMI-for-age z-score, height-for-age z-score, UAFA and fat per-
centage were lower in the Nigerian cohort vs. the São Paulo
cohort (Table 2). A higher proportion of patients from the
Nigeria cohort were wasted, 28 (29.5%) vs. 20 (18.3%), and of
short stature, 12 (12.6%) vs. 4 (3.7%) respectively, while more
International Health
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patients from the São Paulo cohort were overweight or obese,
10 (9.2%) vs. 4 (4.3%) and taller for age, 17 (15.6%) vs. 8
(8.4%) (Figure 1).
Haematological and biochemical parameters
The mean haematocrit, MCV, MCH, MCHC and HbF were signifi-
cantly lower in the Nigerian cohort (Table 3). However, the mean
serum 25-OHD and zinc levels were higher. (Table 2). None of
the Nigerian patients had severe vitamin D deficiency, and only
12.6% (12/95) had either deficiency or insufficiency (Figure 2).
However, among São Paulo cohorts, 3.7% (4/109) had severe
deficiency and 79.8% (87/109) had either deficiency [31.2%
(34/109)] or insufficiency [48.6% (53/109)]. Only 16.5% (18/
109) of the latter were vitamin D sufficient with values >30 ng/ml.
The mean serum zinc levels of the Brazilian children were signifi-
cantly lower (89.7±14.9 ng/ml) than 101.7±13.7 ng/ml for the
Nigerian children, p<0.001. (Table 3). In addition, higher proportion
of Brazilian children, 10.1% (11/109), compared with 1.1% (1/95)
Nigerian children had low serum zinc levels, p=0.007, although the
proportions with normal or high zinc levels were comparable,
Figure 2.
Comparison of the 36 Brazilian patients not
on hydroxyurea therapy with the 95 Nigerian patients
who were also not on hydroxyurea (HU) therapy
In order to exclude hydroxyurea as a confounding variable, we
compared the 36 Brazilian patients with SCD not on HU therapy
with the 95 Nigerian patients who were also not on HU.
(Tables 1 and 2). We found that the results were essentially
similar to when all the 109 Brazilian patients were compared
with Nigerian patients. The rates of significant pain episodes
were still more common among the Nigerian patients, 74.8%
(71/95) vs. 41.7% (15/36), respectively, p<0.001. Also, the rates
of SCD-related hospitalization and transfusion were still more
common among the Brazilian patients, p=0.025 and 0.012,
respectively.
Table 1. Comparison of sociodemographic and clinical parameters between SCD children from the Federal University of Sao Paulo Teaching
Hospital, Sao Paulo, Brazil and Obafemi Awolowo University Teaching Hospital, Ilesa Unit, Nigeria
Parameters Sao Paulo, Brazil Ilesa, Nigeria
n=95
p-value
All patients=109 HU-naive=36
Age (mean±SD) in years 7.4±2.3 7.1±2.2 7.4±2.5 NS
Age groups
4–5 years 28 (25.7) 11 (30.6) 27 (28.4)
6–7 years 30 (27.5) 11 (30.6) 22 (23.2) NS
8–9 years 26 (23.9) 8 (22.2) 23 (24.2)
10–11 years 25 (22.9) 6 (16.7) 23 (24.2)
Gender (M/F), n (%) 51 (46.8)/58 (53.2) 17 (47.2)/19 (52.8) 53 (54.7)/43 (45.3) NS
Socioeconomic class (I/II/III) in % 10.1/41.3/48.6 10.1/41.3/48.6 15.8/56.8/27.4 0.008*
Age at diagnosis
Birth–1 month 93 (85.3) 26 (72.2) 0 (0)
Infancy 13 (11.9) 9 (25.0) 17 (17.9) <0.001
1–5 years 3 (2.8) 1 (2.8) 51 (53.7)
>5 years 0 (0) 0 (0) 27 (28.5)
Hydroxyurea therapy 73 (67.0) 0 (0) <0.001*
Frequency of pain/12 months
Nil pain/year 63 (57.8) 21 (58.3) 24 (25.3)
1–2 VOC/year 29 (26.6) 13 (36.1) 41 (43.2) <0.001
≥3 VOC/year 17 (15.6) 2 (5.6) 30 (31.6)
Frequency of SCD-related admission/12months
Nil 55 (50.5) 17 (47.2) 65 (68.4)
1–2 38 (34.8) 16 (44.4) 26 (27.4) <0.05
≥3 16 (14.7) 3 (8.3) 4 (4.2)
Frequency of SCD-related transfusion/12months
Nil 74 (67.9) 22 (61.1) 81 (85.2)
1–2 29 (26.6) 12 (33.3) 13 (13.7) <0.05
≥3 6 (5.5) 2 (5.6) 1 (1.1)
*p-value refers to the level of difference between 109 Brazilian and 95 Nigerian patients.
S. A. Adegoke et al.
330
D
ow
nloaded from
 https://academ
ic.oup.com
/inthealth/article/9/6/327/4259766 by U
niversidade Federal de Sï¿½
o Paulo user on 24 August 2020
The mean BMI-for-age z-score, height-for-age score, TSF,
UAA, UAFA and fat % were significantly higher among the 36
Brazilian HU-naive patients, p<0.05 in each case. Similarly, the
mean serum 25-OHD and zinc were significantly lower among
the Brazilian compared with Nigerian patients, p<0.001.
Discussion
We compared the nutritional and some clinical parameters of two
cohorts of children with SCD from Ilesa, Nigeria and São Paulo,
Brazil, in order to examine the probable role of environmental fac-
tors on SCD phenotypes. Higher occurrences of underweight and
short stature were observed among Nigerian children with SCD,
while the occurrence of overweight or obesity was higher among
the São Paulo cohort. In addition, prevalence rates of 25-OHD
deficiency and insufficiency were higher among São Paulo children
with SCD. These differences may be due to factors such as timing
of diagnosis, unequal access to comprehensive care, dietary differ-
ences, climate and actual duration of exposure to sunlight.
In Nigeria, the rate of prescription of hydroxyurea is very low. In
a recent survey of doctors in some dedicated SCD clinics in Nigeria,
it was reported that less than ten of the 18 paediatric/adult SCD
clinics prescribed hydroxyurea to individuals with SCD, and this was
mainly only when the patients could afford it.20 As at the present
time, there is no national policy or guidelines on the use of hydro-
xyurea in individuals with SCD in Nigeria, and its use principally
depends on the managing physician. However, in Brazil there are
clear guidelines and policy on HU therapy in patients with SCD with
the Brazil Ministry of Health approving its use in 2002.21
Newborn screening is a strategic component of comprehensive
SCD care. About 85% of the Brazil cohorts were diagnosed in the
newborn period, compared with none in Nigeria. It is known that
early diagnosis significantly impacts on the severity of the disease.
In this study, the average age at diagnosis for Nigerian children
with SCD was 45.6 months, which is consistent with many previ-
ous studies.22,23 This age at diagnosis is remarkably late when
Table 2. Comparison of the nutritional parameters of Brazilian and Nigerian children with sickle cell disease
Nutritional parameters
(mean±SD)
Sao Paulo, Brazil Nigeria (95) p-value* p-value**
All patients (109) HU-naive (36)
BMI-Z score −0.40±1.43 −0.6±2.3 −1.04±1.35 0.001 0.004
HA-Z score 0.28±1.34 0.6±1.8 −0.52±1.33 0.003 0.006
MUAC (cm) 15.52±2.12 15.8±2.6 15.01±2.22 NS NS
TSF (mm) 19.75±3.50 20.3±4.2 16.53±1.44 <0.001 <0.001
UAMA (cm2) 7.06±2.10 6.8±2.5 8.01±3.68 0.027 0.012
UAA (cm2) 19.53±5.66 20.4±7.5 18.27±5.66 NS NS
UAFA (cm2) 12.47±3.94 13.1±5.3 10.26±2.20 <0.001 <0.001
Fat percentage 63.80±4.65 64.3±4.1 57.67±6.33 <0.001 <0.001
25-OHD (ng/ml) 23.3±8.2 20.8±7.5 41.9±9.8 <0.001 <0.001
Zinc (ng/ml) 89.7±14.9 92.2±15.5 101.7±13.7 <0.001 <0.001
NB: BMI-Z score: body mass index, z-score; HA-Z score: height for age, z-score; MUAC, mid-upper arm circumference; TSF, triceps skinfold;
UAMA, upper arm muscle area; UAA, upper arm area; UAFA, upper arm fat area.
Differences in the medians of BMI-Z score and HA-Z score were analysed with Mann–Whitney U-test. Others were analysed with independent
sample t-test.
*p-value refers to the level of significant difference between all Brazilian and Nigerian patients.
**p-value refers to the difference between Brazilian patients who were HU-naive and Nigerian patients (who were also HU-naive).
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Figure 1. Comparison of the nutritional status of children with SCD from
São Paulo Brazil and Ilesa, Nigeria.
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compared to reports from most developed countries.24–28 The
diagnosis of acute chest syndrome, splenic sequestration and
cholelithiasis was more frequently made among the Brazil cohort,
while osteomyelitis was more common among Nigerian patients.
It has earlier been reported that cholelithiasis is not frequent
among Nigerian patients with SCD, probably because of their low
dietary intake of cholesterol and refined fibre-depleted foods.29
Also, most studies among Nigerian patients with SCD reported low
prevalence of splenic sequestration, although the rate of spleno-
megaly is high,30,31 and was found in one study to be about three
times more common than in US counterparts (22.3% compared
with 8%).32 Malaria contributes significantly to persistent spleno-
megaly in Nigeria and in many long-standing cases, there is calcifi-
cation. This may explain why acute sequestration is uncommon,
although many affected children might have died before arrival in
the hospital. Gumiero et al., in their retrospective study of 225
Brazilian children with SCD at the Centro Infantil Boldrini,
Campinas, São Paulo, reported that frequency of cholelithiasis was
45%, and a-third were diagnosed before the age of 10 years, even
though about 50% were asymptomatic.33 Reports of higher fre-
quency of complications among Brazilian patients may, however,
be a reflection of better documentation of these complications,
rather than disease severity. The Brazilian cohorts probably had
more follow-up visits than their Nigerian counterparts (in a bid to
monitor HU therapy) or because of better health care utilization.
Similar to previous reports, a relatively high proportion of the
children in both centres 23.5% (48/204) were wasted. Traditionally,
this is due to high resting metabolic demands associated with
underlying chronic anaemic states. Other factors, such as acute
effects of vaso-occlusion and chronic organ damage, subopti-
mal nutrition, impaired intestinal absorption, micronutrient defi-
ciency especially zinc deficiency, social factors, hormonal and
endocrine dysfunction also account for the poor weight among
the patients.6,34,35
In this study, Nigerian patients were thinner and had reduced
linear growth for age than their Brazilian counterparts. On the
contrary, more Brazilian children were overweight and obese.
Over the past two decades, the average BMI percentile has
been rising in the general paediatric population and even
among those with SCD.6 This observation has been attributed to
increasing affluence with better nutrition, access to care and
treatment advances like hydroxyurea therapy, as exemplified by
the Brazilian patients in this study. It is therefore important to
actively monitor the pattern of weight gain in these children,
especially in those with specific SCD-directed therapies. The
impact of elevated BMI on the morbidity and mortality of chil-
dren with SCD must also be monitored. Appropriate nutrition
and exercise regimens must also be formulated for them, in
order to maintain a healthy weight throughout their lives.6
We also observed that mean serum 25-OHD levels were sig-
nificantly lower, and vitamin D deficiency and insufficiency more
prevalent among Brazilian children with SCD than the Nigerian
patients. While none of the Nigerian patients had severe vitamin
D deficiency (value less than 10 ng/mL), about 4% of the Brazil
patients did. This obvious difference in the levels of vitamin D
demonstrates the sizeable effects of latitude. São Paulo, like
other cities in south-east Brazil experience longer period of cold
weather. Hence, the time spent outdoors, and consequently
Table 3. Comparison of the haematological variables of Brazilian and Nigerian children with sickle cell anaemia
Parameters Brazil (109) Nigeria (95) p-value
Mean±SD Range Mean±SD Range
Haematocrit (%) 26.8±4.8 18.1–48.1 23.5±3.6 12.7–31.4 <0.001
Leucocytes (×109/L) 12.8±6.2 3.9–47.4 14.5±5.2 4.3–36.5 0.044
Platelet counts (×109/L) 422±156 121–763 349±148 43.0–802.0 0.001
MCV(fL) 93.1±12.6 59.7–118.9 79.1±9.3 56.7–106.5 <0.001
MCH (pg) 31.8±5.2 20.2–41.3 26.1±3.5 17.3–33.5 <0.001
MCHC (g/dl) 33.8±2.5 16.9–38.3 33.0±1.6 29.4–35.9 0.016
HbF (%) 23.6±13.8 0–54.1 10.1±6.1 2.3–27.6 <0.001
Comparison was done by independent sample t-test.
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Figure 2. Comparison of serum 25-hydroxyvitamin D and zinc status of
children with SCD.
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periods of exposure to sunlight are reduced and may explain
this high prevalence of vitamin D deficiency. In a report by
Peters et al. in 2009, less than a-third 27.9% (38/136) of
Brazilian adolescents without SCD, in a rural town in São Paulo
practised physical activity outdoors and 17.6% (24/136) of
them regularly applied sunscreen.36 The data also showed that
reduced sunlight exposure alone may not completely explain
high prevalence of vitamin D deficiency or insufficiency among
those adolescents. Only 14.9% of the 136 in that study had
adequate intake of daily vitamin D recommendation of 200 IU.
Their mean vitamin D intake was 140 IU/day, and 60% had vita-
min D insufficiency.36 Low dietary intake of vitamin D rich foods
and increased utilization of vitamin D for bone remodelling
could have been the main contributory factors to the low serum
vitamin D among those São Paulo adolescents.36–38 In the light
of its reported protective effects on musculoskeletal health,
including pain regulation and immunomodulatory benefits, it is
recommended that routine screening for vitamin D status and
subsequent supplementation should be incorporated in the
management plans for Brazilian patients with SCD.
A major limitation to this study was the determination of serum
25-OHD, zinc and haematological parameters in separate labora-
tories of the respective countries. Although similar standard proce-
dures were followed in the two laboratories, accurate comparison
of these variables could be jeopardized by inter-observer errors and
differences in the prevailing laboratory working conditions. The
results would have been more representative if they were done in
the same laboratory. However, the outbreak of Ebola infection at
the time of the study, which led to stringent regulations involved in
the transportation of blood samples, hampered this.
Conclusions
In conclusion, although it is highly commendable that many
Brazilian patients with SCD are now on specific SCD-targeted
treatments, awareness should be made of the possibilities of
these interventions leading to development of overweight and
obesity. Hence, pragmatic efforts should be put in place to limit
their rate of development. Meanwhile, improved SCD care, includ-
ing early diagnosis and hydroxyurea therapy should be embraced
among Nigerian patients, not only to reduce mortality, but also as
a way of improving growth and nutritional status of these chil-
dren. Given the lower income status of Nigerian population, it is
likely that lower food intake, availability and quality may contrib-
ute to the difference in the nutritional states observed in this
study. Our observation of low values of BMI-for-age z-score in
both populations, indicators of very severe acute malnutrition in
this sub-group of children, than in most other paediatric condi-
tions would warrant continued specialized nutritional care by both
paediatric clinical dietitians and physicians. Research is also
needed to determine appropriate nutritional interventions and
exercise regimens for patients with SCD, especially those on SCD-
directed therapy, so as to maintain a healthy weight.
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